Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MYO, LYRA, MDWD, OPTN, XERS, and represent 32.62% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: CYBN (+$5.8M), ABVX (+$5.4M), CLSD, Outlook Therapeutics, UNCY, PYPD, MYO, KPRX, XAIR, CARA.
- Started 12 new stock positions in CARA, ABVX, RZLT, Amylyx Pharmaceuticals, UNCY, CLSD, CYBN, XAIR, BFRI, PYPD. Outlook Therapeutics, KPRX.
- Reduced shares in these 10 stocks: ATXS (-$8.7M), MDGL (-$5.8M), SRPT (-$5.5M), CLRB (-$5.5M), LYRA, TRVI, ASND, MDWD, NVNO, XERS.
- Sold out of its positions in ASND, ATXS, NVNO, MDGL, MACK, RVPH, SRPT, Sarepta Therapeutics Inc. cmn.
- Rosalind Advisors was a net seller of stock by $-15M.
- Rosalind Advisors has $107M in assets under management (AUM), dropping by -11.86%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 34 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Myomo Com New (MYO) | 7.5 | $8.0M | +27% | 2.4M | 3.27 |
|
| Lyra Therapeutics (LYRA) | 6.7 | $7.1M | -39% | 1.1M | 6.22 |
|
| Mediwound Shs New (MDWD) | 6.5 | $6.9M | -19% | 486k | 14.25 |
|
| Optinose (OPTN) | 6.2 | $6.6M | -7% | 4.5M | 1.46 |
|
| Xeris Pharmaceuticals (XERS) | 5.8 | $6.2M | -20% | 2.8M | 2.21 |
|
| Compass Pathways Sponsored Ads (CMPS) | 5.7 | $6.1M | -8% | 734k | 8.32 |
|
| Cybin Ord (CYBN) | 5.4 | $5.8M | NEW | 14M | 0.41 |
|
| Abivax Sa Sponsored Ads (ABVX) | 5.1 | $5.4M | NEW | 378k | 14.30 |
|
| Miragen Therapeutics (VRDN) | 4.9 | $5.3M | -16% | 300k | 17.51 |
|
| Delcath Systems Com New (DCTH) | 4.6 | $5.0M | 1.0M | 4.77 |
|
|
| Profound Medical Corp Com New (PROF) | 4.3 | $4.5M | 533k | 8.53 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 3.8 | $4.0M | 250k | 16.09 |
|
|
| Clearside Biomedical (CLSD) | 3.7 | $4.0M | NEW | 2.6M | 1.53 |
|
| Outlook Therapeutics Com New | 3.5 | $3.7M | NEW | 312k | 11.94 |
|
| Kalvista Pharmaceuticals (KALV) | 3.2 | $3.4M | -4% | 288k | 11.86 |
|
| Trevi Therapeutics (TRVI) | 3.0 | $3.2M | -50% | 926k | 3.45 |
|
| Female Health (VERU) | 2.9 | $3.2M | +12% | 4.5M | 0.70 |
|
| Unicycive Therapeutics (UNCY) | 2.4 | $2.6M | NEW | 1.9M | 1.38 |
|
| Cellectar Biosciences Com New (CLRB) | 2.3 | $2.5M | -69% | 622k | 3.98 |
|
| Polypid (PYPD) | 1.8 | $1.9M | NEW | 416k | 4.60 |
|
| Inspiremd (NSPR) | 1.5 | $1.6M | -25% | 686k | 2.37 |
|
| Kiora Pharmaceuticals Com New (KPRX) | 1.5 | $1.6M | NEW | 2.3M | 0.71 |
|
| Beyond Air (XAIR) | 1.5 | $1.6M | NEW | 904k | 1.74 |
|
| Cara Therapeutics (CARA) | 1.3 | $1.4M | NEW | 1.5M | 0.91 |
|
| Fortress Biotech Inc- Com New (FBIO) | 1.1 | $1.2M | 608k | 2.00 |
|
|
| Spruce Biosciences (SPRB) | 1.1 | $1.2M | -4% | 1.5M | 0.79 |
|
| Talphera Com New (TLPH) | 0.7 | $782k | 759k | 1.03 |
|
|
| Biofrontera Com New (BFRI) | 0.7 | $777k | NEW | 504k | 1.54 |
|
| Geron Corporation (GERN) | 0.6 | $660k | 200k | 3.30 |
|
|
| Rezolute Com New (RZLT) | 0.5 | $510k | NEW | 200k | 2.55 |
|
| Tonix Pharma Hldg Crp Com New (TNXP) | 0.2 | $168k | 901k | 0.19 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.1 | $73k | -90% | 50k | 1.45 |
|
| Invesco Qqq Tr Unit Ser 1 Put Option | 0.0 | $7.0k | -88% | 100k | 0.07 |
|
| Amylyx Pharmaceuticals Call Call Option | 0.0 | $0 | NEW | 50k | 0.00 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024